Thank you to our Foundational and Sustaining members
MAA Day at the Capitol It’s already here – 2021 Virtual Medical Alley Day at the Capitol! Plans are nearly finalized for our day at the state Capitol, so be sure to register for this members-only opportunity by Monday, March 1! While this year’s events will look a bit different, our team is looking forward to connecting […]
Opening Weeks of Session While 2021 began rather eventfully, there was some semblance of tradition and normalcy during the start of this new legislative term. New members were sworn in (albeit virtually), committees began meeting, and bills were introduced. January has been mostly an orientation month: opportunities for legislators to hear overview presentations from various departments across the state with little official business. COVID-19 has […]
Governor Walz’ Latest Executive Order During a press conference on December 18, Governor Tim Walz updated COVID-19 restrictions through Executive Order 20-103. Key points include: Elementary School Reopening On January 18, 2020, all Minnesota elementary schools will be allowed to operate in-person classes, so long as they have the appropriate strategies and safety measures in place. Social Gatherings and Fitness Centers Starting […]
We’ve all seen the reports. Health care costs are expected to rise again. Mercer predicts an increase of 4.4% in 2021, but notes that we must keep in mind the many unknowns facing employer plan sponsors next year, such as COVID-related costs (potentially including vaccines) and delayed or cancelled care. It’s time to control what […]
Brisbane, Australia October 19, 2020 – Nucleus Networks announced today that Symvivo Corporation has received regulatory approval to initiate a Phase 1, first-in-human trial of bacTRL-Spike™, an orally-delivered, room temperature stable DNA vaccine candidate for the prevention of COVID-19. Symvivo has partnered with Nucleus Network, Australia’s largest Phase 1 clinical trials specialist, to initiate a Phase 1 trial evaluating […]
Melbourne, Australia, Friday, 11th September. Australia’s largest Phase 1 clinical trials specialist, Nucleus Network, has this week started the first human trials of a potential COVID-19 treatment developed by Singlomics (Beijing DanXu) Biopharmaceuticals and licensed by BeiGene, Ltd. Twenty-four healthy participants, aged 18 to 59 years of age, have been screened to take part this […]
Melbourne, Australia, Tuesday 26th May, Australia’s largest Phase 1 Clinical trials specialist, Nucleus Network, has today commenced dosing the first human participants for the Phase 1/2 trial of NVX‑CoV2373, a SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, at its Melbourne clinic. Nucleus Network has begun the Phase 1/2 COVID-19 vaccine trial in Australia on behalf of […]
More than three billion people are currently experiencing some form of restriction on their movement or are in lockdown to try to slow the spread of COVID-19. A global race is underway to develop a vaccine or drug treatment to halt the pandemic. The Jenner Institute, University of Oxford, has announced significant progress in developing and […]